Tl. Pedersen et al., IMPAIRED MIGRATION IN-VITRO OF NEUTROPHILS FROM PATIENTS WITH PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA, British Journal of Haematology, 95(1), 1996, pp. 45-51
Migration of neutrophils in patients with paroxysmal nocturnal haemogl
obinuria (PNH) was studied using two different complement-free in vitr
o model systems, subagarose and transendothelial migration. In the sub
agarose migration assay the mean migration distance of PNH neutrophils
was slightly, but significantly, reduced to 1236 mu m (range 753-1586
, n = 6) compared to a normal mean of 1476 mu m (range 1076-1768, n =
6, P = 0.016). By immunocytochemical staining for the urokinase type p
lasminogen activator receptor (uPAR) which is a glycosyl-phosphatidyl-
inositol (GPI) anchored protein expressed by normal, but not by PNH-af
fected, neutrophils, it was shown that the uPAR-positive subpopulation
of normal neutrophils predominated among the faster migrating cells (
60-80% normal cells at the front of migration) while uPAR-negative (i.
e. PNH-affected neutrophils) were more numerous close to the applicati
on well (5-30% normal cells). When migration of neutrophils was tested
across a monolayer of human umbilical vein endothelial cells (HUVEC)
cultured on polycarbonate filters, there was a 3-4-fold impairment of
the migration of the PNH-affected neutrophils both in the absence of s
timulation and after stimulation with fMLP (P<0.001 in both cases). Af
ter IL-1 stimulation of the endothelium the impairment was even more p
ronounced (8-fold difference, P<0.001). When the endothelial cells wer
e grown on collagen-coated filters the impairment of the migration of
PNH neutrophils was less pronounced, but still significant after stimu
lation with fMLP and IL-1 (2-fold, P < 0.05 in both cases). These resu
lts demonstrate that there is a complement-independent impairment of m
igration of neutrophils from patients with PNH which may be related to
their failure to express GPI-linked proteins involved in cell migrati
on and/or adhesion such as the uPA receptor and the CD66b antigen.